NASDAQ:NGM
NGM Biopharmaceuticals Inc. Stock News
$1.54
+0 (+0%)
At Close: May 16, 2024
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NGM Biopharm
NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders
11:41am, Monday, 26'th Feb 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) to affiliates of The Column Group, LP for $1.5
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
09:03am, Monday, 26'th Feb 2024
SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics f
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
04:01pm, Tuesday, 20'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
04:47pm, Wednesday, 17'th Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates
06:47pm, Thursday, 02'nd Nov 2023
NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.59 per share a year ago.
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
06:46pm, Thursday, 03'rd Aug 2023
NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.46 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.59 per share a year ago.
NGM Bio to Participate in Upcoming Investor Conferences
09:00am, Thursday, 25'th May 2023
SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therape
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates
08:20pm, Tuesday, 28'th Feb 2023
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 13.46% and 166.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Tops Revenue Estimates
08:20pm, Thursday, 03'rd Nov 2022
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.28% and 12.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc
After Plunging 59.4% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)
11:22am, Thursday, 03'rd Nov 2022
The heavy selling pressure might have exhausted for NGM Biopharmaceuticals (NGM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stre
3 Best Penny Stocks To Buy Before November According To Insiders
10:59am, Thursday, 20'th Oct 2022
Penny stocks to buy according to insiders in October. The post 3 Best Penny Stocks To Buy Before November According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | Pen
After Plunging 76.6% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)
11:19am, Tuesday, 18'th Oct 2022
NGM Biopharmaceuticals (NGM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnin
NGM's eye drug fails in a Phase 2 clinical trial
08:48am, Monday, 17'th Oct 2022
Shares of NGM Biopharmaceuticals Inc. NGM, -5.94% tumbled 67.4% in premarket trading on Monday after the company said its experimental treatment for an advanced form of macular degeneration did not me
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m